The Most Overlooked Reason Eli Lilly Stock Keeps Surging -- and It Has Nothing to Do With Weight Loss
2026-07-18 01:15
•Reuben Gregg Brewer •The Motley Fool
•• •• Axe Capital view
Eli Lilly’s Growth Beyond Weight Loss: What It Means for SA Investors
Eli Lilly’s surge isn’t just about GLP-1 weight-loss drugs but smarter pipeline expansion—here’s why that matters for the rand and local markets.
Eli Lilly’s impressive run, led by blockbuster GLP-1 weight-loss drugs like Mounjaro, is often seen purely as a health fad play. But the less talked about angle is how it’s using those profits to build a more stable future with acquisitions in immunology and oncology. This diversification reduces the risk of a sudden revenue drop when patents expire. For South African investors, the direct stock play on Eli Lilly isn’t straightforward, but the USD/ZAR offers a useful lens. Strong US pharmaceuticals with solid pipelines tend to support risk appetite and USD strength. If Eli Lilly’s momentum continues, expect modest support to the rand from investment flows into tech and healthcare-linked assets. Be cautious though: a sharper US dollar rally could pressure the rand regardless. Local counters like Aspen and Adcock Ingram might benefit if rand weakness pushes up pricing power or exports. I’d watch USD/ZAR closely and consider exposure to defensive sectors in SA for balance. this is just my opinion and not financial advice
Watch USD/ZAR for signs of strength or weakness linked to global pharma gains. Locally, hold defensive healthcare stocks like Aspen or Adcock Ingram but avoid rushing into US pharma ETFs via rand-hedged products right now.
- USD/ZAR
- Aspen
- Adcock Ingram
- US dollar sharp appreciation hurting rand-linked assets
- Glitches in Eli Lilly’s pipeline leading to profit setbacks
6/10
While Eli Lilly's GLP-1 weight-loss drugs (Mounjaro and Zepbound) account for nearly two-thirds of revenues with strong growth, the company is strategically using profits from these drugs to build a diversified pipeline in immunology, oncology, and neuroscience through acquisitions like AtaiBeckley and Ventyx Biosciences. Non-weight-loss drugs are already showing 160% revenue growth, positioning Eli Lilly for long-term success beyond the limited patent life of GLP-1 drugs.
This article was originally published by The Motley Fool and has been adapted here for Axe Capital Trading News.
Publisher: The Motley Fool
Author: Reuben Gregg Brewer
Categories: Equities, Earnings
Tickers: LLY, NVO
Sentiment: Positive - The company is demonstrating strong revenue growth from GLP-1 drugs (125-80% YoY) while proactively building a diversified pipeline in immunology, oncology, and neuroscience through strategic acquisitions. Non-weight-loss drugs are showing exceptional 160% growth, reducing long-term dependency risk on GLP-1 products facing patent expiration. Mentioned as the initial market leader in GLP-1 drugs with Wegovy, but Eli Lilly's superior weight-loss results have allowed it to take market share. No additional strategic initiatives or pipeline diversification mentioned.
Keywords: GLP-1 drugs, Mounjaro, Zepbound, immunology, acquisitions, patent expiration, pipeline diversification, oncology
Insights:
- LLY: Positive: The company is demonstrating strong revenue growth from GLP-1 drugs (125-80% YoY) while proactively building a diversified pipeline in immunology, oncology, and neuroscience through strategic acquisitions. Non-weight-loss drugs are showing exceptional 160% growth, reducing long-term dependency risk on GLP-1 products facing patent expiration.
- NVO: Neutral: Mentioned as the initial market leader in GLP-1 drugs with Wegovy, but Eli Lilly's superior weight-loss results have allowed it to take market share. No additional strategic initiatives or pipeline diversification mentioned.